Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Veradermics, Incorporated before investing.

In this article, we go over a few key elements for understanding Veradermics, Incorporated’s stock price such as:

• Veradermics, Incorporated’s current stock price and volume
• Why Veradermics, Incorporated’s stock price changed recently
• Upgrades and downgrades for MANE from analysts
• MANE’s stock price momentum as measured by its relative strength

About Veradermics, Incorporated (MANE)

Before we jump into Veradermics, Incorporated’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Want to learn more about Veradermics, Incorporated’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Veradermics, Incorporated.

Veradermics, Incorporated’s Stock Price as of Market Close

As of September 15, 2026, 4:00 PM, CST, Veradermics, Incorporated’s stock price was $103.890.

Veradermics, Incorporated is up 2.15% from its previous closing price of $101.700.

During the last market session, Veradermics, Incorporated’s stock traded between $100.010 and $105.260. Currently, there are approximately 40.44 million shares outstanding for Veradermics, Incorporated.

Veradermics, Incorporated’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Veradermics, Incorporated Stock Price History

Veradermics, Incorporated’s (MANE) price is currently up 5.57% so far this month.

During the month of September, Veradermics, Incorporated’s stock price has reached a high of $105.260 and a low of $95.420.

Over the last year, Veradermics, Incorporated has hit prices as high as $131.240 and as low as $32.000.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Veradermics, Incorporated Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 15, 2026, there were 0 analysts who downgraded Veradermics, Incorporated’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Veradermics, Incorporated’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Veradermics, Incorporated’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Veradermics, Incorporated (MANE) by visiting AAII Stock Evaluator.

Relative Price Strength of Veradermics, Incorporated

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 15, 2026, Veradermics, Incorporated has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Veradermics, Incorporated is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Veradermics, Incorporated Stock Price: Bottom Line

As of September 15, 2026, Veradermics, Incorporated’s stock price is $103.890, which is up 2.15% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Veradermics, Incorporated stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.